Background: Most totally blind people have non-24-hour sleep–wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker.
Vanda Pharmaceuticals Inc.has announced that the European Commission (EC) approved Hetlioz (tasimelteon) for the treatment of non-24-hour sleep-wake disorder (Non-24)...
Vanda Pharmaceuticals has announced positive results from the SET (Safety and Efficacy of Tasimelteon) Phase III study, evaluating tasimelteon, a...
Vanda Pharmaceuticals has announced publication of pivotal trial results related to patient entrainment in the August issue of The Lancet....
Vanda Pharmaceuticals Inc.has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted...
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug...
Data from SET and RESET Phase III studies of VEC 162 (tasimelteon), from Vanda Pharmaceuticals, for the treatment of Non-24-Hour...
Vanda Pharmaceuticals Inc. has announced the submission of a New Drug Application (NDA) to the FDA for VEC 162 (tasimelteon),...